Cantor Fitzgerald set a $13.00 target price on Viewray (NASDAQ:VRAY) in a research report sent to investors on Monday morning. The brokerage currently has a buy rating on the stock. Cantor Fitzgerald also issued estimates for Viewray’s FY2017 earnings at ($1.03) EPS and FY2018 earnings at ($0.59) EPS.
A number of other equities research analysts have also weighed in on VRAY. ValuEngine lowered shares of Viewray from a hold rating to a sell rating in a research note on Friday, September 22nd. Mizuho reissued a buy rating and set a $12.00 price objective on shares of Viewray in a research note on Tuesday, September 26th. Northland Securities reissued a buy rating and set a $10.00 price objective on shares of Viewray in a research note on Friday, November 17th. Finally, BidaskClub lowered shares of Viewray from a buy rating to a hold rating in a research note on Saturday, December 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $11.20.
Shares of Viewray (NASDAQ VRAY) traded up $0.49 on Monday, hitting $9.62. 902,700 shares of the stock were exchanged, compared to its average volume of 970,943. The company has a market cap of $616.67, a price-to-earnings ratio of -8.83 and a beta of 17.60. The company has a debt-to-equity ratio of -1.67, a current ratio of 1.59 and a quick ratio of 1.20. Viewray has a 52-week low of $3.01 and a 52-week high of $10.39.
Viewray (NASDAQ:VRAY) last announced its earnings results on Monday, November 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The firm had revenue of $12.20 million for the quarter, compared to analysts’ expectations of $18.63 million. The business’s revenue for the quarter was up 2950.0% on a year-over-year basis. sell-side analysts expect that Viewray will post -0.93 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. HighTower Advisors LLC boosted its stake in Viewray by 5.0% during the second quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock worth $135,000 after acquiring an additional 1,000 shares in the last quarter. EAM Investors LLC boosted its stake in Viewray by 7.0% during the second quarter. EAM Investors LLC now owns 202,713 shares of the company’s stock worth $1,312,000 after acquiring an additional 13,243 shares in the last quarter. Dynamic Technology Lab Private Ltd boosted its stake in Viewray by 37.3% during the third quarter. Dynamic Technology Lab Private Ltd now owns 50,281 shares of the company’s stock worth $290,000 after acquiring an additional 13,657 shares in the last quarter. Nationwide Fund Advisors boosted its stake in Viewray by 843.2% during the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock worth $107,000 after acquiring an additional 14,789 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Viewray by 95.9% during the third quarter. Wells Fargo & Company MN now owns 37,802 shares of the company’s stock worth $218,000 after acquiring an additional 18,502 shares in the last quarter. 50.02% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Cantor Fitzgerald Analysts Give Viewray (VRAY) a $13.00 Price Target” was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.truebluetribune.com/2018/01/11/cantor-fitzgerald-analysts-give-viewray-vray-a-13-00-price-target.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.